Changes in benign prostatic hyperplasia management in Valencia: A real-world evidence analysis

被引:0
|
作者
Navarro-Perez, J. [1 ]
Alcina, E. Lopez [2 ]
Perez, J. Calabuig [3 ]
Munto, F. Brotons [4 ]
Martinez, A. [5 ]
Vallejo, L. [6 ]
Jimenez, J. [6 ]
机构
[1] Univ Valencia, Hosp Clin Univ Valencia, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Inst Invest Sanitaria INCLIVA, Valencia, Spain
[2] Consorcio Hosp Gen Univ Valencia, Serv Urol, Valencia, Spain
[3] Conselleria San Universal & Salud Publ, Serv Anal Sistemas Informac Sanitaria, Valencia, Spain
[4] Ctr Salud Trinitat, Valencia, Spain
[5] GlaxoSmithKline, Dept Med, Madrid, Spain
[6] GlaxoSmithKline, Dept Market Access, Madrid, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2024年 / 48卷 / 06期
关键词
Benign prostatic hyperplasia; Training program; Primary care; Real-world study; URINARY-TRACT SYMPTOMS; GUIDELINES;
D O I
10.1016/j.acuro.2023.11.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: A training program was developed to increase general practitioners' engagement in the optimal management of benign prostatic hyperplasia (BPH). The goal of this study was to evaluate changes in BPH management after the implementation of a training program. Material and methods: This observational retrospective cohort study was conducted between 2019 and 2020. Aggregated data were analyzed in 3 evaluation periods (2010, 2012 and 2015), addressing quality indicators for diagnosis, treatment, and treatment outcomes. Results: Overall, 118,795 patients who presented any data points were included. All quality indicators (number of IPSS and PSA determinations) increased between the first period and the last. Combination (alpha-blocker + 5-ARI) therapy was increasingly prescribed during the study periods whereas the proportion of prescriptions for single -agent alpha-blocker showed no significant differences among the periods analyzed. However, the total number of patients eligible for combination therapy who actually received this treatment was low in all periods (7.5, 17.9, and 20.1%, in 2010, 2012, and 2015, respectively). The outcome indicators revealed a decrease in referrals to the Urology unit mostly among newly diagnosed patients. Even though the proportion of patients who underwent BPH-related surgeries increased significantly from the first to the second period, the number of surgeries remained stable between the second and third periods. Conclusions: The training program had a generally positive impact on the management of BPH patients in primary care, but the overall study period may be insufficient to show an effect on some outcome indicators such as the number of surgeries. (c) 2024 The Authors. Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of AEU. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:461 / 469
页数:9
相关论文
共 50 条
  • [11] Real-World Use of Permixon® in Benign Prostatic Hyperplasia - Determining Appropriate Monotherapy and Combination Treatment
    Perry, Richard
    Milligan, Gary
    Anderson, Peter
    Gillon, Andrew
    White, Maren
    ADVANCES IN THERAPY, 2012, 29 (06) : 538 - 550
  • [12] USE OF A FRENCH CLAIMS DATABASE TO ESTIMATE REAL-WORLD TREATMENT COSTS OF BENIGN PROSTATIC HYPERPLASIA
    Jouaville, S. L.
    DiNicola, S.
    Boutmy, E.
    VALUE IN HEALTH, 2015, 18 (03) : A187 - A187
  • [13] Surgical management of benign prostatic hyperplasia: current evidence
    Abdulaziz Baazeem
    Mostafa M Elhilali
    Nature Clinical Practice Urology, 2008, 5 : 540 - 549
  • [14] Surgical management of benign prostatic hyperplasia: current evidence
    Baazeem, Abdulaziz
    Elhilali, Mostafa M.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (10): : 540 - 549
  • [15] MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA
    BOYD, SD
    NARAYAN, P
    WESTERN JOURNAL OF MEDICINE, 1994, 160 (02): : 165 - 166
  • [16] Management of benign prostatic hyperplasia
    Malbos, Damien
    ACTUALITES PHARMACEUTIQUES, 2022, 61 (618): : 50 - 54
  • [17] Management of Benign Prostatic Hyperplasia
    Kim, Eric H.
    Larson, Jeffrey A.
    Andriole, Gerald L.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 137 - 151
  • [18] Management of benign prostatic hyperplasia
    Barry, M
    Roehrborn, C
    ANNUAL REVIEW OF MEDICINE, 1997, 48 : 177 - 189
  • [19] Medical management of benign prostatic hyperplasia in the light of available evidence
    Naikoo, Zahoor Ahmed
    Wani, Mohammed Saleem
    Bhat, Arif Hamid
    TURKISH JOURNAL OF UROLOGY, 2010, 36 (04): : 418 - 429
  • [20] Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases
    Yang, Dae Yul
    Seo, Won-Woo
    Park, Rae Woong
    Rhee, Sang Youl
    Cha, Jae Myung
    Hah, Yoon Soo
    Jeong, Chang Won
    Kim, Kyung-Jin
    Yang, Hyeon-Jong
    Kim, Do Kyung
    Ha, Ji Yong
    WORLD JOURNAL OF MENS HEALTH, 2025, 43 (01): : 188 - 196